Department of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, New York, United States of America.
PLoS One. 2012;7(6):e38759. doi: 10.1371/journal.pone.0038759. Epub 2012 Jun 6.
Recent findings suggest that modulation of ion channels might be implicated in some of the clinical effects of coxibs, selective inhibitors of cyclooxygenase-2 (COX-2). Celecoxib and its inactive analog 2,5-dimethyl-celecoxib, but not rofecoxib, can suppress or augment ionic currents and alter functioning of neurons and myocytes. To better understand these unexpected effects, we have recently investigated the mechanism of inhibition of human K(v)2.1 channels by a highly selective COX-2 inhibitor SC-791. In this study we have further explored the SC-791 action on ion channels and heartbeat in Drosophila, which lacks cyclooxygenases and thus can serve as a convenient model to study COX-2-independent mechanisms of coxibs. Using intracellular recordings in combination with a pharmacological approach and utilizing available Drosophila mutants, we found that SC-791 inhibited voltage-activated K(+) and L-type Ca(2+) channels in larval body-wall muscles and reduced heart rate in a concentration-dependent manner. Unlike celecoxib and several other K(+) channel blockers, SC-791 did not induce arrhythmia. Instead, application of SC-791 resulted in a dramatic slowing of contractions and, at higher concentrations, in progressively weaker contractions with gradual cessation of heartbeat. Isradipine, a selective blocker of L-type Ca(2+) channels, showed a similar pattern of heart arrest, though no prolongation of contractions was observed. Ryanodine was the only channel modulating compound of those tested additionally that was capable of slowing contractions. Like SC-791, ryanodine reduced heart rate without arrhythmia. However, it could not stop heartbeat completely even at 500 µM, the highest concentration used. The magnitude of heart rate reduction, when SC-791 and ryanodine were applied together, was smaller than expected for independent mechanisms, raising the possibility that SC-791 might be interfering with excitation-contraction coupling in Drosophila heart.
最近的研究结果表明,离子通道的调节可能与 COX-2(环氧化酶-2)选择性抑制剂 Coxibs 的一些临床效果有关。塞来昔布及其无活性类似物 2,5-二甲基塞来昔布,但罗非昔布不能抑制或增强离子电流,并改变神经元和心肌细胞的功能。为了更好地理解这些意外的效果,我们最近研究了高度选择性 COX-2 抑制剂 SC-791 对人 K(v)2.1 通道的抑制机制。在这项研究中,我们进一步探讨了 SC-791 对离子通道和果蝇心跳的作用,果蝇缺乏环氧化酶,因此可以作为研究 Coxibs 中 COX-2 非依赖性机制的方便模型。我们使用细胞内记录与药理学方法相结合,并利用现有的果蝇突变体,发现 SC-791 以浓度依赖的方式抑制幼虫体壁肌肉中的电压激活型 K(+)和 L-型 Ca(2+)通道,并降低心率。与塞来昔布和其他几种 K(+)通道阻滞剂不同,SC-791 不会引起心律失常。相反,SC-791 的应用导致收缩明显减慢,并且在较高浓度下,收缩逐渐减弱,心跳逐渐停止。Isradipine 是 L-型 Ca(2+)通道的选择性阻滞剂,也表现出类似的心脏骤停模式,尽管没有观察到收缩的延长。在另外测试的调节通道的化合物中,只有 Ryanodine 能够减缓收缩。与 SC-791 一样,Ryanodine 降低心率而不引起心律失常。然而,即使在 500µM 的最高浓度下,Ryanodine 也不能完全停止心跳。当 SC-791 和 Ryanodine 一起应用时,心率降低的幅度小于预期的独立机制,这表明 SC-791 可能干扰果蝇心脏的兴奋-收缩耦联。